Company intelligence / Profile preview

Karen Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Karen Pharmaceutical is a leading producer of nutritional supplements and pharmaceuticals in Iran with a growing presence in the Middle East and Hong Kong SAR. The company has over 200 products across supplements and pharmaceuticals. It holds GMP certification since 2016 for pharmaceutical manufacturing. Its clinical pipeline includes at least one Phase 3 trial investigating oral supplementation plus vitamin D3 for diabetic sarcopenia; it also manufactures approved small molecule drugs such as phenazopyridine hydrochloride for pain relief.

Therapeutic areas: Metabolic DisordersEndocrinologyOtherPsychiatryGastroenterologyCardiovascularNeurologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Mass Global Nutrition Canada (collaboration on raw materials/supplement development)

Beyond the preview

Go deeper on Karen Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karen Pharmaceutical.